← Back to Search

Janus Kinase (JAK) Inhibitor

Baricitinib for Allergic Contact Dermatitis

Phase < 1
Waitlist Available
Led By Jeffrey B Travers, MD, PhD
Research Sponsored by Wright State Physicians
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28
Awards & highlights

Study Summary

This trial will study whether Baricitinib can improve allergic contact dermatitis, a skin reaction that is often unsatisfactory to treat. Males between 18 and 40 who are healthy can participate by having antigens injected and applied to their skin, then being monitored for effects via skin and blood testing.

Eligible Conditions
  • Allergic Contact Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Hypersensitivity
Number of participants with reduced skin inflammation associated with Delayed-Type Hypersensitivity (DTH) versus irritant skin reactions by measurement of reaction size.
Number of participants with reduced skin inflammation associated with Delayed-Type Hypersensitivity (DTH) versus irritant skin reactions by pro-inflammatory cytokine profile.
Secondary outcome measures
Number of participants with reduced pruritus associated with DTH versus irritant skin reactions.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Subjects Taking Baricitinib 2 mgExperimental Treatment1 Intervention
Subjects will be taking Baricitinib 2mg
Group II: Subjects Taking PlaceboPlacebo Group1 Intervention
Subjects will be taking placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Baricitinib
2017
Completed Phase 3
~9510

Find a Location

Who is running the clinical trial?

Wright State PhysiciansLead Sponsor
3 Previous Clinical Trials
73 Total Patients Enrolled
Jeffrey B Travers, MD, PhDPrincipal InvestigatorWright State Physicians
9 Previous Clinical Trials
237 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects
2020. "Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03945760.
~5 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top